Children's Hospital Colorado

Physicians Represent Children's Colorado at International Symposium on Pediatric Neuro-Oncology

Children's Hospital Colorado | June 29, 2018

The 18th International Symposium on Pediatric Neuro-Oncology, a unique forum that brings together 1,200 leading researchers, physicians, surgeons, nurses and social workers to exchange information, results and collaborate, is coming to Colorado June 29 - July 3. This is the first time the symposium will be held in the U.S. since 2008, and Children's Colorado is one of the key sponsors of the event.

This symposium brings together oncologists, neurosurgeons, radiation oncologists, neurologists, nurses, researchers, neuropathologists, neuroradiologists, endocrinologists, psychologists and social workers involved in research, diagnosis, treatment, rehabilitation and overall care of children with central nervous system (CNS) tumors.

There will be 800 presentations made by nearly 600 professionals from around the world. Representing the largest cohort from one institution, 28 doctors, nurses and researchers from Children's Colorado and the University of Colorado Anschutz Medical Campus will present their work across 12 plenary talks and 22 posters.

Affected families are invited to the first day of the conference

On June 29, the first day of the session will include a full-day Family Day at our Anschutz Medical Campus, sponsored by The Morgan Adams Foundation. This day is intended for families and patients battling brain tumors and will have sessions on a range of topics including research updates, education issues, nutrition and wellness, care giving and creating a family’s “new normal.” In addition, there will be separate sessions for adults and young adults, as well as a special breakout session for grieving families.

Children's Colorado providers will share their latest neuro-oncology research

Children’s Colorado is proud to be represented by the following providers and researchers who will be speaking at the conference and sharing the latest research outcomes from their fields:

Thomas Inge, MD
Bariatric surgery for treatment of hypothalamic obesity
Sunday, July 1: Quality of Life/Survival/Rehabilitation - 1 - 3 p.m.

Molly Hemenway, NP, PNP, MS
Building a neurofibromatosis therapeutics program
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Andrew Donson
Single cell RNAseq identifies a putative cancer stem cell population in posterior fossa EPN
Sunday, July 1: Ependymoma - 3:30 - 5 p.m.

Anandani Nellan, MD
Study of anti-HER2 CAR T cells in the immunosuppressive ependymoma tumor microenvironment
Sunday, July 1: Ependymoma -  3:30 - 5 p.m.

Carboplatin and vinblastine therapy for pediatric low-grade glioma
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m. 

Nicholas Stence
Imaging characteristics of BRAF V600E mutated pediatric brain tumors
Sunday, July 1: Imaging - 4 - 5 p.m.

Vladimir Amani
Retinoids as potential chemotherapeutic options for posterior fossa ependymoma of childhood
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Erin Kissell
Refining our neuro-oncology multidisciplinary clinic
Sunday, July 1: POSTER SESSION 1 - 5 - 6:30 p.m.

Patrick Flannery
Transcriptional analysis of ATRT samples from long-term survivors and matched primary/recurrent pairs
Sunday, July 1: POSTER SESSION 1 - 5 - 6:30 p.m.

Adam Green
Intratumoral pharmacokinetics of chemotherapy in DIPG: xenograft and initial phase 0 clinical trial results
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m. 

Eric Prince
Leveraging convolutional neural networks to predict adamantinomatous craniopharyngioma diagnosis from preoperative parameters
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Sujatha Venkataraman
Targeting senescent cells with ABT-263 enhances cell death induced by BMI1 inhibition and ionizing radiation in DIPG
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Bethany Veo
The epigenetic regulator, SETD8, facilitates self-renewal and invasion in Myc-driven medulloblastoma.
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Rajeev Vibhakar
Effect of knockdown of KDM6A by CRISPR/CAS9 editing in medulloblastoma
Sunday, July 1: Poster Session 1 - 5 - 6:30 p.m.

Ros Whelan
Inter-rater reliability of a method for determining the pre-operative hypothalamic involvement of pediatric craniopharyngioma
Sunday, July 1: Poster Session 1 -  5 - 6:30 p.m.

Transcriptomic and proteomic comparison of pediatric and adult adamantinomatous craniopharyngioma
Sunday, July 1: Craniopharyngioma/Rare Tumors - 2:30 - 3:30 p.m.

Jean Mulcahy Levy
Analysis of paired BRAFV600E mutant glioma patient samples identifies novel resistance mechanisms to targeted BRAF inhibition
Sunday, July 1: Low Grade Gliomas -  8:45 - 11 a.m.

H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Shadi Zahedi
Assessment of early stage autophagy inhibition in BRAFV600E brain tumor cell response to chemotherapy
Sunday, July 1:  Poster Session 1 - 5 - 6:30 p.m.

Population-based analysis of demographic and socioeconomic disparities in pediatric CNS tumor survival in the United States
Monday, July 2: Epidemiology - 11:30 a.m. - noon

John DeSisto
Comprehensive molecular characterization of pediatric treatment-induced high-grade glioma: germline DNA repair defects as a potential etiology
Monday, July 2: High Grade Glioma -  3:30 - 5 p.m.

Subgroup-specific therapy options for childhood supratentorial ependymoma
Monday, July 2: POSTER SESSION 2 - 5 - 6:30 p.m.

Kathleen Doris, MD
Molecular biology and phase I study of GM-CSF and intrathecal trastuzumab in children with recurrent posterior fossa ependymoma
Monday, July 2: Early Phase Trials - 9:30 - 10:30 a.m.

Improvement in visual acuity of pediatric patients with brain tumors with bevacizumab
Monday, July 2: Poster Session 2 -  5 - 6:30 p.m.

Use of cannabinoids in the pediatric central nervous system tumor population
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Jessica Channell
Quality of life in survivors of childhood brain tumors
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m. 

Nathan A. Dahl
Pediatric craniopharyngioma in association with familial adenomatous polyposis
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

The oncogenic role of the super elongation complex in H3K27M-mutant diffuse midline gliomas
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m. 

Ahmed Gilani
Non-targeted mutation and fusion analyses can aid in classification and treatment of pediatric gliomas
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Andrea Griesinger
Patient-derived PFA ependymoma xenograft model
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Davis Witt
Identification and investigation of a novel epigenetic modulator in posterior fossa ependymoma, SIRT2
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Melissa Waters
Nursing impact on bone marrow transplant in the outpatient setting
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Gregory Norris
Diagnostic accuracy of neuroimaging in pediatric optic pathway/sellar/suprasellar tumors
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Irina Alimova
Targeting SIRT2 in SMARCB1 deficient ATRT
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Paraag Bhatt
Sporadic meningiomas of the pediatric population: A review of neuroradiological, neuropathological, and neuro-oncological attributes
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Etienne Danis
Deciphering and targeting EZH2 overexpression in medulloblastoma
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Rakeb Lemma
The H3K27M mutation causes wide-ranging changes mediating DIPG tumorigenesis
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Krishna Madhavan
Delivery of chemotherapeutics to pediatric brain tumors using citrate-capped gold nanoparticles
Monday, July 2: Drug Delivery

Andrew Morin
Validation of proteasome inhibition as a therapeutic target in atypical teratoid/rhabdoid tumors
Monday, July 2: Poster Session 2 - 5 - 6:30 p.m.

Ismail Sola
EZH2 overexpression increases the oncogenic character of cerebellar progenitors and isografts in mice result in tumors resembling group 3 medulloblastoma
Tuesday, July 3: Medulloblastoma - Basic/Translational Research - 9 - 10:20 a.m.

PRODWEBSERVER2